# OnCo record paper-nct02453282-jama-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct02453282-jama-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct02453282-jama-oncol-2020" ;
  schema:name "Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial"@en ;
  schema:description "Published report from the MYSTIC trial registered as NCT02453282, in JAMA Oncology (2020), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct02453282-jama-oncol-2020/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2020.0237>, <https://pubmed.ncbi.nlm.nih.gov/32271377/>, <https://europepmc.org/article/MED/32271377>, <https://clinicaltrials.gov/study/NCT02453282> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2020.0237> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Rizvi NA, Cho BC, Reinmuth N, et al." ;
  onco:trials <https://onco.cc/trials/nct02453282/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .